154 related articles for article (PubMed ID: 28457410)
1. Immunomodulation, Acute Renal Failure, and Complications of Basiliximab Use After Liver Transplantation: Analysis of 114 Patients and Literature Review.
de Ataide EC; Perales SR; Bortoto JB; Peres MAO; Filho FC; Stucchi RSB; Udo E; Boin IFSF
Transplant Proc; 2017 May; 49(4):852-857. PubMed ID: 28457410
[TBL] [Abstract][Full Text] [Related]
2. Initial immunosuppression with or without basiliximab: a comparative study.
Martín-Mateos RM; Graus J; Albillos A; Arocena C; Rodríguez Gandía MA; Blesa C; García-Hoz F; García González M; García-Alonso FJ; Bárcena R
Transplant Proc; 2012 Nov; 44(9):2570-2. PubMed ID: 23146457
[TBL] [Abstract][Full Text] [Related]
3. Basiliximab With Delayed Tacrolimus Improves Short-Term Renal Outcomes Post-Liver Transplantation-a Real-World Experience.
Boyd A; Brown A; Patel J; Nightingale P; Perera MTPR; Ferguson J; Neuberger J; Rajoriya N
Transplant Proc; 2021 Jun; 53(5):1541-1547. PubMed ID: 34074467
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
[TBL] [Abstract][Full Text] [Related]
5. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.
Keown P; Balshaw R; Khorasheh S; Chong M; Marra C; Kalo Z; Korn A
BioDrugs; 2003; 17(4):271-9. PubMed ID: 12899644
[TBL] [Abstract][Full Text] [Related]
6. Routine induction therapy in living donor liver transplantation prevents rejection but may promote recurrence of hepatitis C.
Ghanekar A; Kashfi A; Cattral M; Selzner N; McGilvray I; Selzner M; Renner E; Lilly L; Levy G; Grant D; Greig P
Transplant Proc; 2012 Jun; 44(5):1351-6. PubMed ID: 22664014
[TBL] [Abstract][Full Text] [Related]
7. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
[TBL] [Abstract][Full Text] [Related]
8. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab.
Heilman RL; Reddy KS; Mazur MJ; Moss AA; Post DJ; Petrides S; Mulligan DC
Transplant Proc; 2006 Jun; 38(5):1307-13. PubMed ID: 16797289
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
[TBL] [Abstract][Full Text] [Related]
10. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
11. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
[TBL] [Abstract][Full Text] [Related]
12. Induction immunosuppressive therapy in renal transplantation: does basiliximab make the difference?
Jorge S; Guerra J; Silva S; Santana A; Mil-Homens C; Prata MM
Transplant Proc; 2008 Apr; 40(3):693-6. PubMed ID: 18454989
[TBL] [Abstract][Full Text] [Related]
13. Quadruple immunosuppression with basiliximab, tacrolimus, mycophenolate mofetil and prednisone is safe and effective for renal transplantation.
Miura M; Harada H; Fukuzawa N; Iwami D; Taniguchi A; Seki T; Togashi M; Ogawa Y; Satoh H; Hirano T
Clin Transplant; 2005; 19 Suppl 14():54-8. PubMed ID: 15955170
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
Neuhaus P; Clavien PA; Kittur D; Salizzoni M; Rimola A; Abeywickrama K; Ortmann E; Chodoff L; Hall M; Korn A; Nashan B;
Liver Transpl; 2002 Feb; 8(2):132-42. PubMed ID: 11862589
[TBL] [Abstract][Full Text] [Related]
15. A benefit-risk assessment of basiliximab in renal transplantation.
Boggi U; Danesi R; Vistoli F; Del Chiaro M; Signori S; Marchetti P; Del Tacca M; Mosca F
Drug Saf; 2004; 27(2):91-106. PubMed ID: 14717621
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
17. Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation.
Flaman F; Zieroth S; Rao V; Ross H; Delgado DH
J Heart Lung Transplant; 2006 Nov; 25(11):1358-62. PubMed ID: 17097501
[TBL] [Abstract][Full Text] [Related]
18. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.
Calmus Y; Scheele JR; Gonzalez-Pinto I; Jaurrieta EJ; Klar E; Pageaux GP; Scudamore CH; Cuervas-Mons V; Metselaar HJ; Prestele H; Girault D
Liver Transpl; 2002 Feb; 8(2):123-31. PubMed ID: 11862588
[TBL] [Abstract][Full Text] [Related]
19. Basiliximab: a review of its use as induction therapy in renal transplantation.
McKeage K; McCormack PL
BioDrugs; 2010 Feb; 24(1):55-76. PubMed ID: 20055533
[TBL] [Abstract][Full Text] [Related]
20. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
